« Back
Home /
Linifanib

Linifanib

Item no.	TMO-T2514-50mg
Manufacturer	TargetMol
CASRN	796967-16-3
Amount	50 mg
Quantity options	100 mg 10 mM x 1 mL (in DMSO) 10 mg 1 mL 200 mg 25 mg 2 mg 500 mg 50 mg 5 mg
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Purity	0,98
Smiles	Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	AL-39324, ABT-869, RG3635
Similar products	796967-16-3
Shipping condition	Cool pack
Available
Manufacturer - Targets	PDGFR\|\|\|Apoptosis\|\|\|FLT\|\|\|CSF-1R\|\|\|Autophagy\|\|\|c-Fms\|\|\|VEGFR\|\|\|c-Kit
	KIT
Shipping Temperature	cool pack
Storage Conditions	-20°
Molecular Weight	375, 4
Target names or alias	RG3635 , ABT-869 , AL-39324
Description	Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: 66 nM). Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).
Pathways	Angiogenesis\|\|\|Tyrosine Kinase/Adaptors\|\|\|Apoptosis\|\|\|Autophagy

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T2514-50mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 50 mg

available

Request delivery time